Contraceptive Market are expected to reach US$ 30.8 Billion by 2032 | FMI

  Global Contraceptive Market are expected to grow at a CAGR of 5.5%, and contraceptive drugs and devices are expected to reach US$ 30.8 Billion by 2032.

According to the report, growing need of population control, increasing incidence of unwanted pregnancies and government’s initiatives drive the contraceptive market forward. It uses unique research methods to offer the most accurate analysis of the market.

Get Full Access @ https://www.futuremarketinsights.com/reports/contraceptives-market

It includes in-depth insights into the contraceptives market. Some of these are:

  • The estimated value of the contraceptives market was at ~US$ 33,529 Mn in 2019. Through the course of the report’s forecast period, the market is exhibited to show a steady pace of growth.
  • Regionally, North America dominates the contraceptives market globally.
  • East Asia emerges as one of key markets owing to large population base, growing contraceptive awareness and initiatives taken by the respective country government.
  • Female segment holds the most of the contraceptive market as compared to men.
  • Key players are likely to focus on new product development in terms of drug & device, to stay relevant in developed markets.

Some of the leading players operating in the contraceptives market are Bayer AGPfizer Inc., Janssen Global Services, LLC, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mylan N.V., Allergan Plc, Reckitt Benckiser Group plc, Veru Inc., Medisafe Distribution Inc., Cooper Surgical, Inc., Mayer Laboratories, Inc., Pfizer, The Female Health Company and others. As a result of increasing competition, companies are focusing on expanding their product portfolio with new innovation. In addition to this, mergers and acquisition remains a popular strategy among market players. Companies intend to expand their regional footprint through strategic collaborations.

  • As a part of government’s initiative, the government of India had launched a new contraceptive pill named ‘Shukhi 3rd Generation’ in Nov 2019.
  • In Spet. 2019, Exeltis USA, Inc. had announced the Launch of Slyndhttps://s.w.org/images/core/emoji/14.0.0/72x72/2122.png(drospirenone) tablets, the First and only progestin-only pill providing pregnancy prevention with a 24-hour missed pill window

 

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research pr
Read more

Companion Diagnostics Market Recent Trends, Dynamic Innovation in Technology & Insights 2032

Image
  The global Companion Diagnostics Market is expected to generate approximately US$ 5152.064939 million by 2032, up from US$ 2452.653722 million in 2022, at a CAGR of 7.1% during the forecast period. With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Companion Diagnostics market. To read more about this report, visit @ https://www.futuremarketinsights.com/reports/companion-diagnostics-market FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Companion Diagnostics market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision. Over the past decade, healthcare sector has been expanding remarkably, followi
Read more

Hospital Consumables Market is expected to reach valuation of US$ 853.2 Billion | FMI

  According to Future Market Insights' newly released Hospital Consumables market analysis report, global Hospital Consumables market sales in 2021 are expected to be US$ 346 billion. The estimated market growth of 12.5% between 2022 and 2032 is expected to be much greater than the previous trend. The consumables market is estimated to have a total revenue opportunity of US$ 853.2 billion. The increase in chronic diseases, medical operations, and the expanding older population are driving market expansion. To learn more about this report @ https://www.futuremarketinsights.com/reports/hospital-consumables-market With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Hospital Consumables market. FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Hospita
Read more